500 UNICORN PARK, WOBURN, MA
Replimune Group, Inc. Increases Authorized Shares to 300 Million
Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Amended material disclosure
Announces Pricing of $150.0 Million Underwritten Offering
FDA Accelerated Approval Investor Call August 6, 2026
Other Events, Press Release
Investor Presentation
Annual Report to Security Holders
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Submission Upload
Correspondence